A novel risk stratification model, involving preoperative lymphocyte-monocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy

To evaluate the ability of preoperative lymphocyte-monocyte ratio to predict prognosis and determine post-operative risk stratification in patients with bladder cancer undergoing radical cystectomy.

A retrospective review of the 210 patients who had undergone radical cystectomy for bladder cancer from 2006 to 2013 identified 181 patients with sufficient data to evaluate the prognostic significance of the lymphocyte-monocyte ratio. Overall survival was assessed by the Kaplan-Meier method. The association of clinicopathological findings with overall survival was evaluated by a multivariate Cox proportional model, and a novel risk stratification model to predict prognosis was established.

Median follow-up after radical cystectomy was 6. 0 years. The 5-year overall survival rate was significantly lower for patients with low than high lymphocyte-monocyte ratio (27. 6 vs 80. 7%, P < 0. 001). Multivariable analyses showed that pT ≥2, pN ≥1, positive margins and low lymphocyte-monocyte ratio were independent predictors of overall survival. A post-operative risk stratification model using these factors showed significant differences among the three subgroups (low, intermediate and high risk) with a concordance index of 0. 84. The 5-year overall survival rates in patients at low, intermediate and high risk were 85. 4, 45. 5 and 0%, respectively (P < 0. 001).

Preoperative lymphocyte-monocyte ratio, pathological tumor and lymph node stage and positive margins are significantly associated with overall survival in patients who have undergone radical cystectomy for bladder cancer.

Japanese journal of clinical oncology. 2015 Sep 29 [Epub ahead of print]

Takashi Yoshida, Hidefumi Kinoshita, Kenji Yoshida, Masaaki Yanishi, Hidekazu Inui, Yoshihiro Komai, Motohiko Sugi, Takaaki Inoue, Takashi Murota, Tadashi Matsuda

Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka kinoshih@hirakata. kmu. ac. jp. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka. , Department of Urology and Andrology, Takii Hospital, Kansai Medical University, Osaka, Japan. , Department of Urology and Andrology, Takii Hospital, Kansai Medical University, Osaka, Japan. , Department of Urology and Andrology, Hirakata Hospital, Kansai Medical University, Osaka.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe